Zibotentan No Extra Help in Refractory Prostate CancerZibotentan No Extra Help in Refractory Prostate Cancer
Adding zibotentan to docetaxel for refractory prostate cancer doesn't improve survival, researchers say. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Prostate Cancer | Taxotere